Aldeyra Therapeutics Inc (NASDAQ:ALDX) has a beta value of 0.82 and has seen 0.48 million shares traded in the recent trading session. The company, currently valued at $373.78M, closed the recent trade at $6.26 per share which meant it lost -$0.41 on the day or -6.15% during that session. The ALDX stock price is -15.02% off its 52-week high price of $7.20 and 50.48% above the 52-week low of $3.10. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.81 million shares traded. The 3-month trading volume is 533.74K shares.
The consensus among analysts is that Aldeyra Therapeutics Inc (ALDX) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.24.
Aldeyra Therapeutics Inc (NASDAQ:ALDX) trade information
Sporting -6.15% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ALDX stock price touched $6.26 or saw a rise of 8.08%. Year-to-date, Aldeyra Therapeutics Inc shares have moved 25.45%, while the 5-day performance has seen it change -5.30%. Over the past 30 days, the shares of Aldeyra Therapeutics Inc (NASDAQ:ALDX) have changed 22.50%. Short interest in the company has seen 3.99 million shares shorted with days to cover at 6.27.
Wall Street analysts have a consensus price target for the stock at $12, which means that the shares’ value could jump 47.83% from the levels at last check today.. The projected low price target is $12.0 while the price target rests at a high of $12.0. In that case, then, we find that the latest price level in today’s session is -91.69% off the targeted high while a plunge would see the stock gain -91.69% from the levels at last check today..
Aldeyra Therapeutics Inc (ALDX) estimates and forecasts
The company’s shares have gained 16.57% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
5 analysts offering their estimates for the company have set an average revenue estimate of -800k for the current quarter. 5 have an estimated revenue figure of 54.8M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 15.99% over the past 5 years.
ALDX Dividends
Aldeyra Therapeutics Inc is expected to release its next earnings report on 2025-Feb-27 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders
Insiders own 2.43% of the company shares, while shares held by institutions stand at 63.12% with a share float percentage of 64.70%. Investors are also buoyed by the number of investors in a company, with Aldeyra Therapeutics Inc having a total of 159.0 institutions that hold shares in the company. The top two institutional holders are PERCEPTIVE ADVISORS LLC with over 9.28 million shares worth more than $30.7 million. As of 2024-06-30, PERCEPTIVE ADVISORS LLC held 15.6121% of shares outstanding.
The other major institutional holder is KNOLL CAPITAL MANAGEMENT, LLC, with the holding of over 5.48 million shares as of 2024-06-30. The firm’s total holdings are worth over $18.12 million and represent 9.2158% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Dec 31, 2024 , the former fund manager holds about 2.95% shares in the company for having 1.76 shares of worth $10.74 million while later fund manager owns 1.29 shares of worth $7.9 million as of Feb 28, 2025 , which makes it owner of about 2.16% of company’s outstanding stock.
